SAN FRANCISCO—Pear Therapeutics has posted $64 million in new fundraising on the heels of scoring an FDA clearance last month for its prescription software … Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway. By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.© 2020 EquityZen Inc. All rights reserved. Get the full list », You’re viewing 5 of 19 investors. Personalize which data points you want to see and create visualizations instantly. TOKYO, Dec 8 (Reuters) - SoftBank Group Corp's 9984.T Vision Fund 2 has led an $80 million Series D financing round in digital therapeutics startup Pear Therapeutics … BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that it has successfully closed a $64 million Series C … Pear Therapeutics Inc. is a software-based biotechnology company based in Massachusetts, USA. The company's platform combines novel digital interventions with drugs to enhance efficacy well beyond anything that is commercially available or in clinical development, enabling clients to get better outcomes for patients, smarter engagement and tracking tools for clinicians and cost-effective services for payors. Biotech & Pharma. Developer of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy via Prescription Digital Therapeutics (PDT). Curalie. The company combines pharmaceutical therapy with software technology, such as digital applications and games. Description Developer of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy via Prescription Digital Therapeutics (PDT). EquityZen is a marketplace for shares of proven pre IPO tech companies. Pear Therapeutics is the leader in prescription digital therapeutics. FOUNDED. The Molecular Assemblies story began more than 30 years ago as co- founders, Dr. Bill Efcavitch and Curt Becker, Pear Therapeutics launches digital insomnia app through direct-to-patient telehealth model, Pear Therapeutics Announces Publication of Real-World Healthcare Resource Utilization Data for reSET-O®, Coverage for Pear Therapeutics’ PDTs continues to grow, Pear Therapeutics Announces Collaboration with Apricity Health to Advance Prescription Digital Therapeutics to be Prescribed in Combination with Immuno-oncology Therapy, Pear Therapeutics Expands Pipeline with Machine Learning, Digital Therapeutic and Digital Biomarker Technologies. Pear Therapeutics is a privately held eHealth company with offices in Boston and San Francisco. The top 10 competitors average 378. Pear Therapeutics, also referred to as Pear, is a company developing drug-software combination therapies to help people with mental and behavioral health issues. Pear Therapeutics, Inc. is the leader in prescription digital therapeutics. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. The Company develops digital therapies to address a broad range of severe conditions including addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and sleep. By Dave Muoio. Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, … PitchBook is a financial technology company that provides data on the capital markets. On our trusted digital marketplace for private companies. Developer of a software-based digital therapeutics platform designed to treat disease and enhance the efficacy via Presc, t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons, ex ea commodo consequat.